E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Indolent B-cell Non-Hodgkin’s Lymphoma |
|
E.1.1.1 | Medical condition in easily understood language |
Cancer in the blood or lymphoma |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10025320 |
E.1.2 | Term | Lymphomas non-Hodgkin's B-cell |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To establish effectiveness of ofatumumab in combination with
bendamustine in patients with indolent B-cell NHL disease relapsed
after rituximab therapy. |
|
E.2.2 | Secondary objectives of the trial |
· To establish effectiveness of ofatumumab in combination with bendamustine in subjects with follicular lymphoma refractory to rituximab-containing therapy
· To evaluate and compare ORR, OS, time to and duration of response, and (TTP) in subjects treated with ofatumumab and bendamustine combination therapy to those treated with bendamustine alone
· To evaluate and compare ORR, OS, time to and duration of response, and (TTP) in subjects with follicular lymphoma treated with ofatumumab and bendamustine combination therapy to those treated with bendamustine alone
· To evaluate and compare the safety and tolerability in subjects treated with ofatumumab and bendamustine combination therapy to those treated with bendamustine alone
· To evaluate and compare the two treatment arms with respect to changes in subjects’ health-related Quality of life
Please refer to the Protocol. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects eligible for enrollment in the study must meet all of the
following criteria:
1. Small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma,
marginal
zone lymphoma, and follicular lymphoma; grades 1, 2 and 3A, defined
according to World Health Organization guidelines. Subjects with a
diagnosis
of SLL who have a peripheral blood monoclonal B lymphocyte count of
≥5,000/μL are considered to have CLL and are not eligible for this study.
• Tumor verified to be CD20+ positive from a previous or current tissue
biopsy.
•CT imaging in screening phase (based on local evaluation) showing 2 or
more clearly demarcated lesions/nodes with a long axis >1.5 cm and
short axis ≥ 1.0 cm or 1 clearly demarcated lesion/node with a long axis >2.0 cm and short axis ≥1.0 cm (Section 6.2.5 of Study Protocol). CT imaging performed at screening as baseline image.
2. Indolent B-cell NHL with failure to achieve at least a partial response
lasting 6 months beyond the end of treatment with rituximab or a rituximabcontaining regimen (See Section 6.2.5.4– Section 6.2.5.5 of study protocol for details on response criteria), i.e.:
•Stable disease (SD) after rituximab or a rituximab-containing regimen
(imaging will support this finding. NOTE: in cases of SD after rituximab
monotherapy as induction treatment, the minimum time to confirm SD
by imaging is 60 days from start of first rituximab infusion) or,
• Disease progression during or within 6 months of treatment with
rituximab or a rituximab-containing regimen. Imaging must support this
finding and will be done ≤ 6 months after the last infusion of rituximab.
Note: Subjects must have received a minimum of 4 rituximab infusions
as monotherapy or 3 infusions as part of rituximab-containing
combination regimens
3. ECOG Performance Status of 0, 1, or 2
4. Age ≥ 18 years
5. Life expectancy of at least 6 months
6. Signed written informed consent prior to performing any studyspecific procedures
French subjects: In France, a subject will be eligible for inclusion in this
study only if either affiliated to or a beneficiary of a social security category |
|
E.4 | Principal exclusion criteria |
Subjects meeting any of the following criteria will not be enrolled in the
study:
1. Grade 3b FL or evidence that the indolent lymphoma has transformed to aggressive lymphoma as verified by biopsy confirmation
2. Previous autologous stem cell transplant in the last 6 months or
previous allogeneic stem cell transplant at any time.
3. High dose steroids ≥ 25 mg prednisolone/day (or equivalent) for 7
consecutive days, given as concomitant medication, within 3 months prior to randomization. No more than 10 mg prednisone daily at the time of randomization
4. Prior bendamustine treatment within 1 year of randomization not
resulting in a CR or PR for at least 6 months
5. Prior use of any monoclonal antibody (other than anti-CD20) within 3
months prior to randomization
6. Known central nervous system (CNS) involvement by indolent
lymphoma
7. Other past or current malignancy. Subjects who have been free of
malignancy for at least 5 years, or have a history of definitively treated nonmelanoma skin cancer, or successfully treated in situ carcinoma, are eligible*
8. Chronic or current active infectious disease requiring systemic
antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, and active Hepatitis C
9. Clinically significant cardiac disease as judged by the investigator
including unstable angina, acute myocardial infarction within 6 months of randomization, congestive heart failure, and arrhythmia requiring therapy
10. History of significant cerebrovascular disease or event with
significant symptoms or sequelae
11. Significant concurrent, uncontrolled medical condition that in the
opinion of the investigator or GSK medical monitor contraindicates
participation this study
12. Positive serology for Hepatitis B (HB) defined as a positive test for
Hepatitis B surface antigen (HbsAg). In addition, if negative for HBsAg but Hepatits B core antibody (HBcAb) positive (regardless of HBsAb status), a HBV DNA test will be performed and if positive the subject will be excluded
● Consult with a physician experienced in care and management of
subjects with Hepatitis B to manage/treat subjects who are anti-HBc positive
● If HBV DNA is negative, subject may be included but must undergo HBV DNA monitoring (see Section 6.5.7.1 of study protocol). Prophylactic antiviral therapy may be initiated at the discretion of the investigator
13. Current active liver or biliary disease (subjects with Gilbert's
syndrome or asymptomatic gallstones, liver metastases related to indolent NHL or otherwise stable chronic liver disease per investigator assessment, are eligible)
14. Known human immunodeficiency virus (HIV) positive
15. Screening laboratory values:
● platelets < 100 x 109/L (unless due to indolent lymphoma involvement
of the bone marrow)
● neutrophils < 1.5 x 109/L (unless due to indolent lymphoma
involvement of the bone marrow)
● Serum creatinine > 1.5 times the institution's upper limit of normal
(ULN); subjects with a serum creatinine > 1.5 ULN will be eligible if the
calculated creatinine clearance [Cockcroft, 1976] or creatinine clearance from a 24- hour urine collection is 40 mL/min
● Total bilirubin > 1.5 times ULN (unless due to liver involvement by FL
or Gilbert's disease)
● Transaminases > 3 times ULN
16. Known or suspected hypersensitivity to ofatumumab, bendamustine, or mannitol
17. Treatment with any known non-marketed drug substance or
experimental therapy within 5 terminal half-lives or 4 weeks prior to Visit 1, whichever is longer or currently participating in any other interventional clinical study
18. Known or suspected inability to comply with study protocol
19. Lactating women, women with a positive pregnancy test at Visit 1 or women (of childbearing potential) as well as men with partners of
childbearing potential, who are not willing to use adequate contraception from study start through one year following last treatment dose. Adequate contraception is defined as
abstinence, oral hormonal birth control, hormonal birth control
injections, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, intrauterine device, and male partner sterilization if male partner is sole partner for that subject. The double barrier method can be used in regions where considered acceptable and adequate (condom and/or occlusive cap plus
spermicidal agent, as per local acceptable standards)
*Subjects can participate in the study if in the opinion of the investigator and medical monitor it is thought not to affect the subject's safety, the conduct of the study or the interpretation of the data |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Progression-free survival, defined as the time interval between randomization and disease progression or death |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Please refer to the complete list of timings that can be found in
Appendices 1-3 of the study protocol. |
|
E.5.2 | Secondary end point(s) |
Clinical
-Progression-free survival in patients with follicular lymphoma
· Overall response rate (ORR) in all patients and patients with follicular lymphoma
· Overall survival (OS) in all patients and patients with follicular lymphoma
· Time to response and duration of response in all patients and patients with follicular lymphoma
· Time to progression and time to next therapy in all patients and patients with follicular lymphoma
· Changes in health-related quality of life (HRQL) measures in all patients and patients with follicular lymphoma
· Reduction in tumor size
· Improvement in Eastern Cooperative Oncology Group (ECOG) Performance status
· Incidence and severity of AEs, serious adverse events (SAEs) and other safety parameters including frequency of transfusions, development of Human Anti-Human Antibodies (HAHA), incidence of 3 and 4 infections, and myelosuppression (anemia, neutropenia, and thrombocytopenia)
· Overall response rate (ORR) to ofatumumab monotherapy in subjects in Arm B who progress during or following single-agent bendamustine
· Changes in clinical laboratory values
· Quantitative assessments of immunoglobulins G, A and M (IgG, IgA, IgM)
· Plasma ofatumumab concentrations
· B-cell monitoring (CD19+, CD20+)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Please refer to the complete list of timings that can be found in
Appendices 1-3 of the study protocol. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 70 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Austria |
Belgium |
Brazil |
Canada |
France |
Germany |
Greece |
Hong Kong |
Italy |
Japan |
Poland |
Russian Federation |
Slovakia |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be the Last Subject Last Visit after 5 year follow up |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 12 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |